Sat, Jul 12, 2014, 2:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Weyerhaeuser Co. Message Board

miamigent1 10 posts  |  Last Activity: 18 hours ago Member since: May 18, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Sell or hold?

    by jbpsb1 Jun 19, 2014 8:43 AM
    miamigent1 miamigent1 18 hours ago Flag

    With such a large gap up, one thought would be to relinquish half and rebuy later- gaps usually fill, at least somewhat.
    GL.
    MG

  • Reply to

    HOLLOW (CELG & market) sell-off!

    by boar292hog Jul 8, 2014 1:25 PM
    miamigent1 miamigent1 Jul 10, 2014 12:32 AM Flag

    Yes, it's rainy season in So. FL.- clouds, thunder, lightning and rain in afternoon but day starts sunny.
    MG

  • Reply to

    HOLLOW (CELG & market) sell-off!

    by boar292hog Jul 8, 2014 1:25 PM
    miamigent1 miamigent1 Jul 9, 2014 10:38 PM Flag

    Better hope the past is no guide- EPS growth last 5 years has been +.16% (deplorable).
    MG

  • Reply to

    HOLLOW (CELG & market) sell-off!

    by boar292hog Jul 8, 2014 1:25 PM
    miamigent1 miamigent1 Jul 9, 2014 9:29 PM Flag

    I don't see the market ahead as robust as you. Crowdsourcing will grow, impairing the market some.
    MG

  • Reply to

    HOLLOW (CELG & market) sell-off!

    by boar292hog Jul 8, 2014 1:25 PM
    miamigent1 miamigent1 Jul 9, 2014 9:24 PM Flag

    I don't see CELG as cheap- it's trading at 12.8 x's book and 101 x's tangible book. And that's only using tonight's close, not the recent highs you use in your assertion.
    MG

  • Reply to

    Get Out NOW!!!

    by buddy4sports Jun 25, 2014 6:22 PM
    miamigent1 miamigent1 Jun 26, 2014 11:32 PM Flag

    Absolutely- 90% of downtown Miami sales are to foreigners and almost all cash.
    Thank goodness for foreigners buying R.E. in the U.S.
    MG

  • Reply to

    PLUG: Don't Fight The Trend...

    by miamigent1 May 19, 2014 10:09 PM
    miamigent1 miamigent1 May 19, 2014 11:23 PM Flag

    I am very conservative as far as indicating what others might do.
    If my prior posts are checked, I rarely make a recommendation. So "Buy" is pretty strong for me, lol.
    Thanks for affirmation of my post.
    MG

  • PLUG Up 3.65% a day, on average over last six days:

    5-19-14 4.49 close from prior 4.29 close = +4.66%
    5-16-14 4.29 close from prior 4.03 close = +6.45%
    5-15-14 4.03 close from prior 3.82 close = +5.50%
    5-14-14 3.82 close from prior 4.09 close = -6.60%
    5-13-14 4.09 close from prior 3.90 close = +4.87%
    5-12-14 3.90 close from prior 3.72 close = +4.84%
    5-09-14 3.72 close from prior 3.64 close = +2.20%

    The shorts are being squeezed.

    MG

    Sentiment: Buy

  • My post today:
    VLTC Picked up small amount today for lotto bounce play.
    PPS drop yesterday to 1/3 book value
    Float about 3.7M
    Carl & family in, believe it or not
    V. low vol- may grow beard waiting for exit

    My post yesterday:
    Bad Q yesterday: lost biggest cust, AT&T; about 7 fold decline in earnings (-5M vs 200K, Q over Q); moved biz to new neighborhood called "Negative Shareholder Equity".

  • miamigent1 by miamigent1 Apr 17, 2014 2:34 PM Flag

    Raises 2014 and 2015 Guidance significantly on "robust" sales of gallstone drug
    In it.

    Retrophin Ups 2014, 2015 Revenue Guidance; FDA Not Yet Approved Clinical Trial For RE-024 - Seeing Higher Pre-Bell Bid of $15.51
    BY Midnight Trader — 7:15 AM ET 04/14/2014

    Retrophin (RTRX) raised its revenue guidance for 2014 and 2015 as reimbursement for its Chenodal drug to treat gallstones was "robust."

    The pharmaceutical company said it now expects sales of between $19 million and $21 million in 2014, up from the previous guidance of $10 million to $12 million. For 2015, it expects sales between $35 million and $40 million compared to the previous guidance range between $19 million and $21 million.

    "The success of Chenodal significantly reduces our cash needs and may propel the company to profitability in the near-term," CEO Martin Shkreli said in a statement. "As such, we have no need or desire to explore a dilutive equity offering unless it is accompanied by an accretive and strategic acquisition. Retrophin (RTRX) remains opportunistic with respect to M&A and has strong access to both debt and equity capital."

    RTRX closed down nearly 16% on Friday, near the mid-point of the 52-week range between $4.50 and $24.25. The stock was bid higher in recent pre-market trade.

    The company said it received an update from clinical investigators on Friday regarding its RE-024 for the ultra-orphan disease Pantothenate Kinase-Associated Neurodegenerationthat, that the U.S. Food Administration had so far been unwilling to grant a clinical trial.

    "The small delay is frustrating to all of our stakeholders, but we expect the issue will be resolved in the near term and we are taking steps to grow our R&D infrastructure to avoid similar experiences in the future," Shkreli said.

WY
32.38-0.19(-0.58%)Jul 11 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.